Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Entrada Therapeutics Inc. Common Stock
TRDA | US
12.31
USD0.26
2.16%
TRDA | US
About Entrada Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
26/03/2026
Close
12.31
Open
11.95
High
12.52
Low
11.84
Entrada Therapeutics Inc. a biotechnology company develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide antibody and enzyme-based programs. The company's lead therapeutic candidates which include ENTR-601-44 and ENTR-601-45 which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501 an intracellular thymidine phosphorylase enzyme replacement therapy which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701 which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research develop manufacture and commercialize ENTR-701. The company was formerly known as CycloPorters Inc. and changed its name to Entrada Therapeutics Inc. in October 2017. Entrada Therapeutics Inc. was incorporated in 2016 and is headquartered in Boston Massachusetts.
View LessTRDA | US
Risk
67.8
Sharpe
0.25
Luna's Score
69/100
Recommendation
Buy
Luna says (TRDA | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Smallcap (300M - 2B USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
52.9%1 month
67.8%3 months
59.5%6 months
61.5%Returns
Fundamental Ratios
PE
5.77
Fwd. PE
3.33K
Price to book
1.51
Debt to equity
0.15
Debt to assets
0.11
Ent. to EBITDA
2.51
Ent. to rev.
1.02
PEG
-
Other Fundamentals
EBITDA
96.87M
MarketCap
457.93M
MarketCap(USD)
457.93M
Div. yield
-
Op. margin
56.42
Erngs. growth
-
Rev. growth
421.20
Ret. on equity
32.80
Short ratio
12.80
Short perc.
8.79
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.46
Range1M
2.69
Range3M
4.33
Volumes: Market Activity
Rel. volume
0.60
Price X volume
1.70M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.51 | - | Expensive |
| Ent. to Revenue | 1.02 | - | Cheaper |
| PE Ratio | 5.77 | 41.03 | Cheaper |
| Price to Book | 1.51 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 59.48 | - | Par |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.11 | 0.25 | Cheaper |
| Market Cap | 457.93M | - | Emerging |
